Update on the newer antiepileptic drugs in child neurology: Advances in treatment of pediatric epilepsy

2007 ◽  
Vol 9 (6) ◽  
pp. 395-403 ◽  
Author(s):  
Mazin Abdul ◽  
James J. Riviello
2014 ◽  
Vol 5 (3) ◽  
pp. 118
Author(s):  
Rajat Rana ◽  
Soumadip Das ◽  
S Ramesh ◽  
S Chidambaramnathan ◽  
Ajit Singh ◽  
...  

2007 ◽  
Vol 37 (3) ◽  
pp. 200-202 ◽  
Author(s):  
D. Barry Sinclair ◽  
Laura Jurasek ◽  
Matt Wheatley ◽  
Anita Datta ◽  
Donald Gross ◽  
...  

2021 ◽  
Author(s):  
Michael C Kaufman ◽  
Julie Xian ◽  
Peter D Galer ◽  
Shridhar Parthasarathy ◽  
Alexander K Gonzalez ◽  
...  

Introduction Determining the long-term impact of telemedicine in care across the diagnostic and age spectrum of child neurology during the COVID-19 pandemic and with the re-opening of outpatient clinics. Methods An observational cohort study of 34,837 in-person visits and 14,820 telemedicine outpatient pediatric neurology visits between October 1, 2019 and April 9, 2021. We assessed differences in care across visit types, time-period observed, time between follow-ups, patient portal activation rates and demographic factors. Results 26,399 patients were observed in this study (median age 11.4 years [interquartile range, 5.5-15.9]; 13,209 male). We observed a higher proportion of telemedicine for epilepsy (ICD10 G40: OR 1.4, 95% CI 1.3-1.5) and a lower proportion for movement disorders (ICD10 G25: OR 0.7, 95% CI 0.6-0.8; ICD10 R25: OR 0.7, 95% CI 0.6-0.9). Infants were more likely to be seen in-person after re-opening clinics than by telemedicine (OR 1.6, 95% CI 1.5-1.8) as were individuals with neuromuscular disorders (OR 0.6, 95% CI 0.6-0.7). Racial and ethnic minority populations and those with highest social vulnerability had lower rates of telemedicine participation throughout the pandemic (OR 0.8, 95% CI 0.8-0.8; OR 0.7, 95% CI 0.7-0.8). Discussion Telemedicine implementation was followed by continued use even once in-person clinics were available. Pediatric epilepsy care can often be performed using telemedicine while young children and patients with neuromuscular disorders often require in-person assessment. Prominent barriers for socially vulnerable families and racial and ethnic minorities persist.


2002 ◽  
Vol 17 (2_suppl) ◽  
pp. 2S2-2S8 ◽  
Author(s):  
Patricia K. Crumrine

This review article presents information concerning treatment options for various pediatric epilepsy syndromes. The decisions made in the selection of antiepileptic drugs are determined by a number of variables that include, but are exclusive of, risk of seizure recurrence, patient age, epilepsy syndrome, known drug reactions, and prognosis of the epilepsy syndrome. The review discusses issues pertinent to antiepileptic drug selection including simple pharmacokinetic principles, antiepileptic drug formulations, and information concerning clinical studies using some of the antiepileptic drugs. Information is provided concerning the issues of seizure recurrence. Suggested paradigms for antiepileptic drug selection for partial seizures are provided. A table of antiepileptic drug costs is provided for assistance in prescribing and advising families. Psychosocial issues pertinent to the treatment of children are discussed. (J Child Neurol 2002;17:2S2—2S8).


Sign in / Sign up

Export Citation Format

Share Document